Tsinghua University | China
Assoc. Prof. Dr. Lan Xie is a leading researcher in drug discovery and traditional Chinese medicine (TCM) integration with modern biomedical technologies. She earned her M.D. in Clinical Medicine from Peking University and a Ph.D. in Biology from Tsinghua University. Dr. Xie completed postdoctoral training at Tsinghua University and a visiting scholar program at the University of Pittsburgh. She has held faculty positions at Tsinghua University since 2014, currently serving as Associate Professor at the School of Basic Medical Sciences. Her research focuses on combining TCM with systems biology, multi-omics, and artificial intelligence to develop novel therapeutic strategies. She pioneered the Molecular Materia Medica database and an intelligent TCM formulation algorithm leveraging gene expression profiles and dysregulated disease pathways. Her work has been recognized with numerous awards, including the Huaxia Medical Science and Technology Award, International Award for Contribution to Chinese Medicine, and multiple Tsinghua University teaching excellence awards. Dr. Xie’s research achievements encompass high-throughput TCM bioactive component screening, single-cell omics-based mechanistic studies, and pathway-guided intelligent drug formulation. With 1,716 citations by 47 documents, 47 publications, and an h-index of 24, her contributions continue to advance modern medicine by bridging traditional knowledge and cutting-edge technology.
Featured Publications
“A universal gene expression signature-based strategy for the high-throughput discovery of anti-inflammatory drugs.” Inflammation Research. 2025.
“Identification of the fruit of Brucea javanica as an anti-liver fibrosis agent working via SMAD2/SMAD3 and JAK1/STAT3 signaling pathways.” Journal of Pharmaceutical Analysis. 2025.
“Pulsatilla chinensis functions as a novel antihyperlipidemic agent by upregulating LDLR in an ERK-dependent manner.” Chinese Medicine United Kingdom. 2024.
“Mechanism study of Xiaoyao San against nonalcoholic steatohepatitis-related liver fibrosis based on a combined strategy of transcriptome analysis and network pharmacology.” Pharmaceuticals. 2024.